acarbose + sulfonylurea

Acarbose + sulfonylurea is a **combination therapy** used in the management of **type 2 diabetes mellitus**. This therapy combines acarbose, an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, with a sulfonylurea, a class of medications that stimulate insulin secretion from pancreatic beta cells. The primary clinical rationale for this combination is improved glycemic control when monotherapy is inadequate. This combination increases the risk of hypoglycemia compared to acarbose alone due to the insulinotropic effect of sulfonylureas. There is evidence that acarbose may mitigate the weight-increasing effect of sulfonylureas[1][2][5][6].